Alterations of chemotherapeutic pharmacokinetic profiles by drug–drug interactions

Abstract

Background Drug interactions in oncology are common place and largely ignored as we tolerate high thresholds of ‘toxic’ drug responses in these patients. However, in the era of ‘targeted’ or seemingly ‘less toxic’ therapy, these interactions are more commonly flagged and contribute significantly towards poor ‘quality of life’ and medical fatalities. Objective This review and opinion article focuses on alteration of chemotherapeutic pharmacokinetic profiles by drug interactions in the setting of polypharmacy. The assumption is that the drugs, with changes in their pharmacokinetics, will contribute towards changes in their pharmacodynamics. Methods The examples cited for such drug–drug interactions are culled from published literature with an emphasis on those interactions that have been well characterized at the molecular level. Results Although very few drug interaction studies have been performed on approved oncology based drugs, it is clear that drugs whose pharmacokinetics profiles are closely related to their pharmacodynamics will indeed result in clinically important drug interactions. Some newer mechanisms are described that involve interactions at the level of gene transcription, whereby, drug metabolism is significantly altered. However, for any given drug interaction, there does not seem to be a comprehensive model describing interactions. Conclusions Mechanisms based drug interactions are plentiful in oncology; however, there is an absolute lack of a comprehensive model that would predict drug–drug interactions.

A Novel PBPK Modeling Approach to Assess Cytochrome P450 Mediated Drug‐Drug Interaction Potential of the Cytotoxic Prodrug Evofosfamide

“…PBPK simulations of DDI mediated by drug metabolizing enzymes is the area in which substantial scientific and regulatory experience has been gathered so far . In addition, predictive confidence has been demonstrated for interactions via CYPs, so that these approaches can be used for modeling and simulation with high regulatory impact, and generate essential information also for the safe use of cancer drugs in light of the limited studies in humans …”

“…This is unfortunate, because this information is particularly important for drugs with a narrow therapeutic range. DDI studies for cytotoxic anticancer drugs are typically conducted in patients with cancer because traditional chemotherapies are too toxic to be studied in healthy volunteers and, thus, face many challenges, such as restrictions on the study design or higher variability of the data …”

Fangjiomics: In Search of Effective and Safe Combination Therapies

“…The pharmacokinetics of combination therapy as a unit may significantly differ from those of a single‐compound treatment 63 . For example, the area under the plasma concentration versus time curve (AUC) of the disposition of mycophenolic acid was reduced by an average of 10%, 19%, and 33% when given with norfloxacin, metronidazole, and norfloxacin plus metronidazole, respectively, compared with administration of mycophenolate mofetil alone 64 .…”

Effect of the Phragmitis Rhizoma Aqueous Extract on the Pharmacokinetics of Docetaxel in Rats

“…One research demonstrated that the pharmacokinetic profiles and bioavailability of drugs can be affected by co-administered of herbal extracts or their phytochemical compounds though modulating the activity or expression of drug-metabolizing enzymes and/or membrane transporters to regulate the absorption and secretion of drugs [8]. Therefore, when herbal medicines are used to relieve the adverse effects of conventional therapy, the possibility of herb-drug interactions should be carefully investigated to ensure the safe use of herbal medicines as complementary medicine.…”